-
公开(公告)号：US20150185221A1
公开(公告)日：2015-07-02
申请号：US14284324
申请日：2014-05-21
IPC分类号： G01N33/574 , C12Q1/68 , A61K31/496 , A61K31/352 , A61K31/704
CPC分类号： G01N33/57496 , A61K31/05 , A61K31/136 , A61K31/352 , A61K31/353 , A61K31/473 , A61K31/475 , A61K31/496 , A61K31/704 , A61K31/7048 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N2333/914 , G01N2800/52
摘要： Methods for identifying and treating cancer patients likely to respond to topoisomerase inhibitors or likely to fail to respond to topoisomerase inhibitors are provided. The methods take advantage of the newly discovered role of BAF complexes in decatenation of DNA by topoisomerase IIa. Cancer cells are frequently at least partly defective in BAF complex activity. Such cells are targeted for therapy using certain topoisomerase IIa inhibitors according to the disclosed methods of treatment. Therapy of such cells using other topoisomerase inhibitors should be avoided.
摘要翻译： 提供了鉴定和治疗可能对拓扑异构酶抑制剂有反应或可能不能对拓扑异构酶抑制剂作出反应的癌症患者的方法。 该方法利用新发现的BAF复合物在拓扑异构酶IIa对DNA脱氨作用中的作用。 癌细胞在BAF复合物活性中经常至少部分缺陷。 根据公开的治疗方法，使用某些拓扑异构酶IIa抑制剂将这些细胞靶向治疗。 应避免使用其他拓扑异构酶抑制剂治疗这些细胞。
-
公开(公告)号：US10976320B2
公开(公告)日：2021-04-13
申请号：US14284324
申请日：2014-05-21
IPC分类号： G01N33/574 , A61K31/352 , A61K31/704 , A61K31/496 , C12Q1/6886 , A61K31/475 , A61K31/473 , A61K31/05 , A61K31/136 , A61K31/353 , A61K31/7048
摘要： Methods for identifying and treating cancer patients likely to respond to topoisomerase inhibitors or likely to fail to respond to topoisomerase inhibitors are provided. The methods take advantage of the newly discovered role of BAF complexes in decatenation of DNA by topoisomerase IIa. Cancer cells are frequently at least partly defective in BAF complex activity. Such cells are targeted for therapy using certain topoisomerase IIa inhibitors according to the disclosed methods of treatment. Therapy of such cells using other topoisomerase inhibitors should be avoided.
-
搜索结果
2 条记录 (耗时 0.02 秒)
